The Transthyretin Amyloid Cardiomyopathy Treatment market is estimated to be valued at US$ 1687.23 Mn or Mn in 2023 and is expected to exhibit a CAGR of 31. % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, debilitating, and fatal disease characterized by the buildup of amyloid deposits made of misfolded transthyretin protein in the heart muscle. This results in heart dysfunction and heart failure. Currently available treatment options include gene silencing drugs, small molecule stabilizers, and cardiac transplantation.
Market Dynamics:
The growth of the Transthyretin Amyloid Cardiomyopathy Treatment market is mainly driven by advancements in drug development. Major companies are focusing on developing next generation therapies with improved efficacy and safety profiles. For instance, in March 2021, Pfizer received FDA approval for Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for the treatment of ATTR-CM. Additionally, approval of novel gene silencing therapies is also fueling market growth. Eidos Therapeutics received FDA approval for inotersen sodium (TEGSEDI) in 2018 and Ionis Pharmaceuticals received approval for patisiran (Onpattro) in 2018 for treating hereditary amyloid transthyretin-mediated amyloidosis with polyneuropathy.
SWOT Analysis
Strength: Transthyretin Amyloid Cardiomyopathy Treatment Market
- Growing research and development activities by key players to develop innovative treatment options.
- Increasing awareness and diagnosis rate of Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
- Advancements in treatment such as gene silencing therapies and small molecule therapies.
Weakness:
- High cost associated with treatment. Gene silencing therapies such as RNAi therapies are highly expensive.
- Lack of awareness about ATTR-CM in developing regions hampering early diagnosis.
Opportunity:
- Growing geriatric population worldwide increasing the risk of ATTR-CM prevalence.
- Untapped markets in developing regions offer immense growth potential.
- Ongoing clinical trials evaluating various pipeline drugs offer lucrative opportunities.
Threats:
- Stringent regulatory approvals for new drug treatments increasing risks.
- Safety issues associated with gene silencing therapies limit their adoption.
Key Takeaways
The Global Transthyretin Amyloid Cardiomyopathy Treatment Market Size is expected to witness high growth, exhibiting CAGR of 31% over the forecast period, due to increasing prevalence ofATTR-CM driven by growing geriatric population worldwide.
The global Transthyretin Amyloid Cardiomyopathy Treatment market size was valued at US$ 1687.23 Mn in 2023 and is projected to reach US$ 47,784.36 Mn by 2030, expanding at a CAGR of 31% during the forecast period.
North America dominated the global market in 2023 and is expected to continue its dominance over the forecast period. This is attributed to growing awareness about ATTR-CM, availability of advanced treatment options, and presence of major key players in the region. Asia Pacific expected exhibit fastest growth owing to rising healthcare expenditure and increasing focus of key players on tapping opportunities in developing countries.
Key players operating in the Transthyretin Amyloid Cardiomyopathy Treatment market are Pfizer Inc., GlaxoSmithKline Plc., Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc.
Read Our More Blogs : https://www.pressreleasebulletin.com/transthyretin-amyloid-cardiomyopathy-treatment-market-analysis-growth-forecast-outlook-2023-2030/